Sign In

Susan Acker-Walsh

Co-Founder, Managing Partner, CREO, Inc.

Professional Background

Susan Acker-Walsh is a visionary leader with extensive experience in driving profitable growth through innovative strategies across various industries, including health, drug development, and technology. Renowned for her ability to scale companies both organically and through strategic acquisitions, Acker-Walsh has consistently delivered exemplary customer service and fostered high-performing multi-functional teams. Her leadership has been characterized by effective communication with both internal and external stakeholders, as well as her ability to craft compelling presentations for Leadership and Board meetings. Throughout her career, she has held pivotal roles in several high-profile organizations, demonstrating a strong penchant for strategic planning, operations optimization, and team building.

Acker-Walsh was a key member of the leadership team at Constella Group, where she played an instrumental role in growing the company’s EBITDA from $2 million to an impressive ~$20 million. Additionally, her strategic vision helped drive Constella’s revenue from $45 million to nearly $200 million within just four years. Her remarkable accomplishments culminated in the successful sale of Constella Group to a public company at a valuation of 11 times EBITDA, amounting to $189 million—a testament to her foresight and acumen in navigating complex business environments.

Education and Achievements

Susan possesses a strong educational foundation with a Master of Business Administration (MBA) focused on Strategy from the prestigious University of North Carolina at Chapel Hill - Kenan-Flagler Business School. Additionally, she holds a Bachelor’s of Arts degree in History from Mount Saint Mary’s University. Her academic credentials have equipped her with a strategic mindset that she applies to real-world business scenarios.

Beyond her academic achievements, Acker-Walsh's professional journey includes starting and successfully growing Blue292 from inception into a thriving two-division software company. Her leadership prowess was further evidenced when she turned around SRA International's $27 million Global Clinical Development business, expertly positioning it for divestiture. Moreover, she skillfully led the separation following the divestiture of Futures Group, showcasing her exceptional operational expertise.

Core Competencies

Acker-Walsh's competencies span a wide array of essential skills that are crucial for executives in today’s fast-paced business landscape. Her expertise in strategic planning allows her to chart effective growth trajectories for organizations. In addition, her focus on operations optimization ensures that processes are efficient and effective, which is vital for maintaining profitability and growth.

Data-driven analysis and problem-solving are other core strengths, enabling her to make informed decisions that drive results. With a strong background in mergers and acquisitions, as well as negotiations, she has successfully navigated complex business transactions that enhance company value. Her command over business metrics and reporting empowers her to measure success and identify areas for improvement effectively.

Team building and mentoring are at the heart of Acker-Walsh's leadership philosophy. She is committed to developing impactful leaders within her organizations, ensuring a sustainable future for teams and operations. Her project management skills, coupled with a focus on succession planning, make her an invaluable asset to any organization, ensuring customer satisfaction and operational excellence.

Notable Positions Held

Susan Acker-Walsh currently serves as the CEO and Co-Founder of CREO, Inc., where she continues to innovate and inspire in the business world. Her previous roles include:

  • Chief Operating Officer at Clinipace Worldwide, where she led efforts to optimize operations and drive growth.
  • Managing Partner at Acker-Walsh Leadership Consulting, LLC, where she provided strategic guidance to organizations looking to enhance their leadership capacity.
  • President & Chief Operating Officer at SciMetrika, LLC, overseeing various divisions and driving company-wide initiatives.
  • Vice President & Operations Director of the Health & Civil Group at SRA International, where she was pivotal in leading major projects.
  • Senior Vice President of Corporate Organization & People Development at Constella Group, ensuring that the organization was equipped with top talent to meet strategic goals.
  • Chairwoman, President, and CEO at Blue292, overseeing all aspects of the software company’s growth and development.
  • Vice President of Corporate Development at Analytical Sciences, Inc., known later as Constella Group, LLC, where she played a critical role in corporate expansion and strategic development.

Conclusion

Susan Acker-Walsh's career reflects a profound commitment to excellence in leadership, strategy, and operational performance. Her ability to inspire teams, drive growth, and navigate complex business landscapes makes her a standout figure in the sectors she engages with. With a proven track record and a forward-thinking mindset, she continues to set benchmarks in her field, providing invaluable contributions to the organizations she leads and advises.

Related Questions

How did Susan Acker-Walsh contribute to the rapid growth of Constella Group from $45M to nearly $200M in revenue?
What innovative strategies has Susan Acker-Walsh implemented in her role as CEO of CREO, Inc.?
In what ways did Susan Acker-Walsh turn around the $27M Global Clinical Development business for SRA International?
How does Susan Acker-Walsh approach team building and leadership development within her organizations?
What are some key lessons Susan Acker-Walsh has learned through her extensive experience in mergers and acquisitions?
Susan Acker-Walsh
Add to my network

Location

Chapel Hill, North Carolina, United States